Last reviewed · How we verify
NCT05825001
Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers
NA trial testing Smoking Cessation Intervention in Cigarette Smoking-Related Carcinoma in 104 participants. Participants enrolled and being followed up; not accepting new ones.
1 October 2025
Quick facts
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 104 |
| Start date | 15 September 2024 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Smoking Cessation Intervention
- Smoking Cessation Intervention (control)
- Medical Device Usage and Evaluation
Conditions studied
- Cigarette Smoking-Related Carcinoma — all drugs for Cigarette Smoking-Related Carcinoma →
Sponsor
Roswell Park Cancer Institute
Who can join
18 and older, any sex, with Cigarette Smoking-Related Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial evaluates the effectiveness of active episodic future thinking (EFT) stimuli for reducing cigarette consumption in cigarette smokers. EFT is an innovative framing method shown to significantly activate brain regions involved in future thinking, planning, and other executive functions. Active EFT stimuli are positive events, unrelated to smoking, that participants anticipate, look forward to, and can vividly imagine happening up to 1 year in the future. Control EFT stimuli are positive past events, unrelated to smoking, that participants can vividly remember happening in the recent past. Active EFT stimuli may help reduce cigarette consumption among cigarette smokers by exposing them to personally relevant future oriented stimuli.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05825001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Smoking Cessation Intervention
Trials testing the same drug.
- NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
- NCT06145763 — A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial · NA · recruiting
- NCT06213532 — CONNECTing to LungCare · NA · recruiting
- NCT06583148 — A Smoke-Free Home Intervention in Tribal Communities · NA · recruiting
- NCT05941858 — Online Tai Chi Intervention to Promote Smoking Cessation Among Cancer Survivors · NA · completed
Other recruiting trials for Cigarette Smoking-Related Carcinoma
Currently open trials in the same condition.
- NCT06816459 — Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults · EARLY_PHASE1 · recruiting
- NCT07111234 — Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences · NA · recruiting
- NCT06145763 — A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial · NA · recruiting
- NCT06763536 — Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia · NA · recruiting
- NCT07167225 — Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study) · recruiting
Other Roswell Park Cancer Institute trials
Trials by the same sponsor.
- NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
- NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
- NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
- NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05825001 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05825001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing